|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.39 CNY | -0.82% |
|
-2.46% | +10.05% |
Company Valuation: DaShenLin Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51,603 | 33,307 | 37,585 | 28,359 | 17,151 | 22,082 | 22,082 | - |
| Change | - | -35.46% | 12.85% | -24.55% | -39.52% | 28.75% | 0% | - |
| Enterprise Value (EV) 1 | 49,252 | 32,838 | 36,233 | 27,369 | 15,778 | 20,246 | 19,571 | 18,817 |
| Change | - | -33.33% | 10.34% | -24.46% | -42.35% | 28.32% | -3.33% | -3.85% |
| P/E ratio | 48.4x | 42.1x | 36.3x | 24.2x | 18.6x | 18.8x | 15.4x | 13x |
| PBR | 9.93x | 6.3x | 6.24x | 4.16x | 2.49x | 2.91x | 2.65x | 2.38x |
| PEG | - | -1.6x | 1.2x | 1.8x | -0.9x | 0.7x | 0.7x | 0.7x |
| Capitalization / Revenue | 3.54x | 1.99x | 1.77x | 1.16x | 0.65x | 0.8x | 0.72x | 0.65x |
| EV / Revenue | 3.38x | 1.96x | 1.71x | 1.12x | 0.6x | 0.73x | 0.63x | 0.56x |
| EV / EBITDA | 27.5x | 13.6x | 19.2x | 12.9x | 4.65x | 6.19x | 5.24x | 4.34x |
| EV / EBIT | 34x | 31.6x | 25.5x | 16.8x | 10.5x | 10.8x | 8.92x | 7.22x |
| EV / FCF | 42x | 117x | 13.1x | 19.7x | 9.51x | 21.1x | 11.2x | 8.42x |
| FCF Yield | 2.38% | 0.86% | 7.61% | 5.09% | 10.5% | 4.74% | 8.9% | 11.9% |
| Dividend per Share 2 | 0.463 | 0.3472 | 0.5 | 0.31 | 0.31 | 0.581 | 0.6863 | 0.7765 |
| Rate of return | 1.02% | 1.19% | 1.52% | 1.24% | 2.06% | 3% | 3.54% | 4% |
| EPS 2 | 0.9375 | 0.6944 | 0.9083 | 1.03 | 0.81 | 1.032 | 1.261 | 1.492 |
| Distribution rate | 49.4% | 50% | 55% | 30.1% | 38.3% | 56.3% | 54.4% | 52.1% |
| Net sales 1 | 14,583 | 16,759 | 21,248 | 24,531 | 26,497 | 27,582 | 30,825 | 33,878 |
| EBITDA 1 | 1,788 | 2,408 | 1,883 | 2,119 | 3,395 | 3,272 | 3,732 | 4,336 |
| EBIT 1 | 1,448 | 1,041 | 1,421 | 1,632 | 1,501 | 1,872 | 2,195 | 2,604 |
| Net income 1 | 1,062 | 791.2 | 1,036 | 1,166 | 914.8 | 1,180 | 1,435 | 1,696 |
| Net Debt 1 | -2,351 | -469.2 | -1,352 | -989.8 | -1,373 | -1,836 | -2,511 | -3,266 |
| Reference price 2 | 45.34 | 29.24 | 33.00 | 24.90 | 15.06 | 19.39 | 19.39 | 19.39 |
| Nbr of stocks (in thousands) | 1,138,102 | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | 1,138,848 | 1,138,848 | - |
| Announcement Date | 19/04/21 | 27/04/22 | 27/04/23 | 28/04/24 | 25/04/25 | - | - | - |
1CNY in Million2CNY
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.95x | 0.74x | 6.24x | 2.97% | 3.19B | |
| 33.41x | 1.93x | 31.15x | -.--% | 25.08B | |
| 36.98x | 2.17x | 31.92x | -.--% | 12.78B | |
| 18.15x | 0.82x | 8.43x | 1.84% | 6.84B | |
| 21.12x | 1.37x | 9.66x | 3.06% | 4.74B | |
| 17.7x | 1.16x | 8.24x | 2.29% | 4.41B | |
| 16x | 1.41x | 8.44x | 5.39% | 3.45B | |
| 50.2x | - | - | - | 2.19B | |
| 25.58x | 0.78x | 9.74x | 1.58% | 1.96B | |
| Average | 26.45x | 1.30x | 14.23x | 2.14% | 7.18B | |
| Weighted average by Cap. | 29.21x | 1.63x | 22.37x | 1.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 603233 Stock
- Valuation DaShenLin Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition